Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibit… Read more
Ascentage Pharma Group International (AAPG) - Total Liabilities
Latest total liabilities as of June 2025: $2.37 Billion USD
Based on the latest financial reports, Ascentage Pharma Group International (AAPG) has total liabilities worth $2.37 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ascentage Pharma Group International - Total Liabilities Trend (2016–2024)
This chart illustrates how Ascentage Pharma Group International's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ascentage Pharma Group International Competitors by Total Liabilities
The table below lists competitors of Ascentage Pharma Group International ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SPS Commerce Inc
NASDAQ:SPSC
|
USA | $195.97 Million |
|
Lineage, Inc. Common Stock
NASDAQ:LINE
|
USA | $9.81 Billion |
|
TISCO Financial Group Public Company Limited
BK:TISCO
|
Thailand | ฿240.46 Billion |
|
Inner Mongolia MengDian HuaNeng Thermal Power Corp Ltd
SHG:600863
|
China | CN¥17.09 Billion |
|
MiTAC Holdings Corp
TW:3706
|
Taiwan | NT$44.14 Billion |
|
Zai Lab Ltd
NASDAQ:ZLAB
|
USA | $399.00 Million |
|
COFCO Tunhe Sugar Co Ltd
SHG:600737
|
China | CN¥9.61 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Ascentage Pharma Group International's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ascentage Pharma Group International's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ascentage Pharma Group International (2016–2024)
The table below shows the annual total liabilities of Ascentage Pharma Group International from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.34 Billion | -3.54% |
| 2023-12-31 | $2.43 Billion | +0.34% |
| 2022-12-31 | $2.42 Billion | +42.00% |
| 2021-12-31 | $1.71 Billion | +92.82% |
| 2020-12-31 | $884.42 Million | +181.15% |
| 2019-12-31 | $314.57 Million | -85.96% |
| 2018-12-31 | $2.24 Billion | +214.10% |
| 2017-12-31 | $713.46 Million | +17.36% |
| 2016-12-31 | $607.95 Million | -- |